Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.
Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW.
Knight JM, et al.
Blood Adv. 2020 Feb 11;4(3):467-476. doi: 10.1182/bloodadvances.2019000765.
Blood Adv. 2020.
PMID: 32027744
Free PMC article.
Clinical Trial.